Skip to main content
icon for FDA approves Daraxonrasib this year?
Teknolohiya·Drug

FDA approves Daraxonrasib this year?

icon for FDA approves Daraxonrasib this year?
Teknolohiya·Drug

FDA approves Daraxonrasib this year?

87% tsansa
Polymarket
BAGO
87% tsansa
Polymarket
BAGO
Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for a drug product whose active ingredient is Revolution Medicines’ daraxonrasib (including any brand name or identifier) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.Positive Phase 3 RASolute 302 trial results announced in April 2026, later published in the New England Journal of Medicine, provide the main catalyst for the 87.5% market-implied odds of FDA approval for daraxonrasib this year. In previously treated metastatic pancreatic ductal adenocarcinoma, the oral RAS inhibitor delivered a median overall survival of 13.2 months versus 6.7 months with chemotherapy (hazard ratio 0.40), alongside doubled progression-free survival and a manageable safety profile with fewer discontinuations. These data address a critical unmet need in RAS G12-mutated disease, where historical outcomes remain poor. FDA expanded-access authorization and the drug’s targeted mechanism further support accelerated review timelines, though final approval hinges on full data review and agency decisions amid typical oncology regulatory uncertainty.

Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for a drug product whose active ingredient is Revolution Medicines’ daraxonrasib (including any brand name or identifier) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Volume
$2,329
Petsa ng Pagtatapos
Dec 31, 2026
Binuksan ang Market
May 13, 2026, 5:28 PM ET

Resolver

0x65070BE91...
Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for a drug product whose active ingredient is Revolution Medicines’ daraxonrasib (including any brand name or identifier) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for a drug product whose active ingredient is Revolution Medicines’ daraxonrasib (including any brand name or identifier) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.Positive Phase 3 RASolute 302 trial results announced in April 2026, later published in the New England Journal of Medicine, provide the main catalyst for the 87.5% market-implied odds of FDA approval for daraxonrasib this year. In previously treated metastatic pancreatic ductal adenocarcinoma, the oral RAS inhibitor delivered a median overall survival of 13.2 months versus 6.7 months with chemotherapy (hazard ratio 0.40), alongside doubled progression-free survival and a manageable safety profile with fewer discontinuations. These data address a critical unmet need in RAS G12-mutated disease, where historical outcomes remain poor. FDA expanded-access authorization and the drug’s targeted mechanism further support accelerated review timelines, though final approval hinges on full data review and agency decisions amid typical oncology regulatory uncertainty.

Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for a drug product whose active ingredient is Revolution Medicines’ daraxonrasib (including any brand name or identifier) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Volume
$2,329
Petsa ng Pagtatapos
Dec 31, 2026
Binuksan ang Market
May 13, 2026, 5:28 PM ET

Resolver

0x65070BE91...
Daraxonrasib is an RAS inhibitor drug developed by Revolution Medicines and currently in trial to treat RAS-mutated cancers. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for a drug product whose active ingredient is Revolution Medicines’ daraxonrasib (including any brand name or identifier) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Kaugnay

icon for FDA approves Retatrutide this year?

FDA approves Retatrutide this year?

3%
icon for US government bans an open source AI model in 2026?

US government bans an open source AI model in 2026?

16%
icon for US grants license for new nuclear reactor in 2026?

US grants license for new nuclear reactor in 2026?

12%

Mag-ingat sa mga external link.

Mga Madalas na Tanong

Ang "FDA approves Daraxonrasib this year?" ay isang prediction market sa Polymarket kung saan bumibili at nagbebenta ang mga trader ng "Yes" o "No" shares batay sa kung naniniwala silang mangyayari ang event na ito. Ang kasalukuyang crowd-sourced probability ay 87% para sa "Yes." Halimbawa, kung ang "Yes" ay naka-presyo sa 87¢, ang market ay kolektibong nagtatakda ng 87% na tsansa na mangyayari ang event na ito. Patuloy na nagbabago ang mga odds na ito habang tumutugon ang mga trader sa mga bagong development at impormasyon. Ang mga shares sa tamang outcome ay mare-redeem sa $1 bawat isa sa market resolution.

Ang "FDA approves Daraxonrasib this year?" ay isang bagong likhang market sa Polymarket, inilunsad noong May 13, 2026. Bilang isang maagang market, ito ang iyong pagkakataon na maging kabilang sa mga unang trader na magtakda ng odds at mag-establish ng mga paunang price signal ng market. Maaari mo ring i-bookmark ang pahinang ito para subaybayan ang volume at trading activity habang lumalaki ang market sa paglipas ng panahon.

Para mag-trade sa "FDA approves Daraxonrasib this year?," piliin lang kung naniniwala ka na ang sagot ay "Yes" o "No." Ang bawat panig ay may kasalukuyang presyo na sumasalamin sa implied probability ng market. Ilagay ang iyong halaga at i-click ang "Trade." Kung bibili ka ng "Yes" shares at na-resolve ang outcome bilang "Yes," nagbabayad ang bawat share ng $1. Kung na-resolve bilang "No," ang iyong "Yes" shares ay nagkakahalaga ng $0. Maaari ka ring magbenta ng iyong shares anumang oras bago ang resolution kung gusto mong i-lock in ang kita o bawasan ang pagkalugi.

Ang kasalukuyang probability para sa "FDA approves Daraxonrasib this year?" ay 87% para sa "Yes." Ibig sabihin nito na kasalukuyang naniniwala ang Polymarket crowd na may 87% tsansa na mangyayari ang event na ito. Nag-a-update ang mga odds na ito sa real-time batay sa actual trades, na nagbibigay ng patuloy na ina-update na signal kung ano ang inaasahan ng market na mangyayari.

Ang mga resolution rules para sa "FDA approves Daraxonrasib this year?" ay tiyak na nagde-define kung ano ang kailangang mangyari para sa bawat outcome na maideklara bilang panalo — kasama ang mga opisyal na data source na ginagamit para matukoy ang resulta. Maaari mong i-review ang kumpletong resolution criteria sa "Rules" section sa pahinang ito sa itaas ng mga komento. Inirerekomenda namin na basahin nang mabuti ang mga patakaran bago mag-trade, dahil tinutukoy nila ang mga tiyak na kondisyon, edge cases, at mga source na namamahala kung paano nise-settle ang market na ito.